The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic landscape and biomarker analyses utilizing circulating-tumor DNA in advanced esophageal squamous cell carcinoma: Sub-analysis of SCRUM-MONSTAR GOZILA.
 
Yuqing Duan
No Relationships to Disclose
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Takata Pharmaceutical
 
Taro Shibuki
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Amgen; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Yakuhin; Roche; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Naoki Takahashi
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yuta Sato
No Relationships to Disclose
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Tomohiro Nishina
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tomonori Nakanoko
No Relationships to Disclose
 
Shogen Boku
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo Co. Ltd. (Inst)
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); SHIONOGI (Inst); Yakult Honsha (Inst)
 
Hisateru Yasui
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; JMS; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Lilly; MSD; Ono Pharmaceutical; Roche Diagnostics Solutions; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Asahi Kasei (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Nihonkayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Mitsuho Imai
Patents, Royalties, Other Intellectual Property - 1. ?NCC's Reference: #2023-03 Filing number (Filing date): US 63/468,666 (2023.05.24) Title: METHOD OF USING AN ARTIFICIAL INTELLIGENCE-POWERED WHOLE SLIDE IMAGE (WSI) ANALYSIS TO PREDICT TUMOR RESPONSE TO SUBSEQUENT IMMUNE CHECKPOINT INHIBITOR TREATMEN
 
Takao Fujisawa
Honoraria - Amelief; AstraZeneca; Merck Serono
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)